Haifa, Israel (ots/PRNewswire) - Round includes leading international investors, further solidifying MeMed's leadership in host-based diagnostics MeMed today announced the completion of a new round of financing totaling over $70 million, with participation from new and existing investors including Ping An Global ...
Amsterdam (ots/PRNewswire) - Royal Philips (http://www.philips.com/) (NYSE: PHG) (AEX: PHIA), a global leader in health technology, today released a new Future Health Index (FHI) report "Moving data to the heart of health systems: Increasing vital technology adoption to make value-based healthcare a reality ...
Amsterdam and Paris (ots/PRNewswire) - New portable ventilator builds on Philips respiratory clinical excellence to enhance transitional care coordination and collaboration At the European Respiratory Society (ERS) International Congress 2018 in Paris, France (September 15-19), Royal Philips (http://www.usa.philips.com/) (NYSE: PHG) (AEX: PHIA), a global leader in ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...
Cambridge, England (ots/PRNewswire) - - flutiform k-haler is now available in Europe as an asthma treatment for adults and adolescents (aged 12 years and older)[1] - Research indicates that many patients make errors with their inhalers and this is associated with poor asthma control and increased exacerbations[2] - ...
Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held rare disease company today announced the appointment of Hugo Petit as its new Chief Financial Officer. Mr Petit previously served as the Chief Financial Officer of MedCap AB. While at MedCap, Hugo led the company's listing on Nasdaq Stockholm. Prior to joining MedCap, Hugo held several roles as Chief Financial Officer in small as well as medium ...
Geneva (ots/PRNewswire) - Updated Assessment of Breast Cancer Gene Expression Profiling Tests for Clinical Use in Germany Final German Federal Joint Committee (G-BA) Reimbursement Decision Expected by End of 2018 Genomic Health today announced the publication of an updated assessment ...
Petah Tikva, Israel (ots/PRNewswire) - Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system for use with implanted left ventricular assist devices (LVADs), announces the successful completion of a 90-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump. The trial was ...
Munich (ots/PRNewswire) - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high ...
London (ots/PRNewswire) - COMPASS Pathways (https://compasspathways.com/), a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for ...
General Intermediates of Canada
Edmonton, Alberta (ots/PRNewswire) - Edmonton's GIC in pursuit of new immuno-oncology therapy Edmonton's General Intermediates of Canada Inc. (GIC) announced today that they have received conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) related to ...
Tokyo (ots/PRNewswire) - - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in previously treated patients based on data showing improved progression-free survival (PFS) and overall response rate (ORR) when compared to vorinostat. - FDA approval was based ...
Munich (ots/PRNewswire) - - Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE - This analysis provides benefit/risk assessment in different types of ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - German Federal Institute for Drugs and Medical Devices (BfArM) recommends new formulation of Euthyrox® for approval in 21 EU countries - BfArM is acting as a representative of all 21 EU countries involved in the EU worksharing procedure Merck, a leading science and technology company, today ...
Bernardsville, New Jersey (ots/PRNewswire) - Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima's Translation Control Therapeutics platform. (Logo: https://mma.prnewswire.com/media/721538/Anima_Biotech_Logo.jpg ...
Oulu, Finland (ots/PRNewswire) - Company moves to 12.5MEUR in total private funding and appoints new board members with US industry expertise for latest growth phase Oura Health (https://ouraring.com/), the Finnish health technology company behind the Oura ring, has moved its total private funding to 12.5MEUR after the closure of a round led by US-based Bold Capital Partners (http://www.boldcapitalpartners.com/) and ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Fertility.com is the gateway to two online portals: - Offering the latest scientific information to healthcare professionals in the advancing field of fertility - Supporting women, men and couples who are looking for information about fertility and/or undergoing fertility treatment (Photo: ...
Brussels (ots/PRNewswire) - - NEUPRO now approved in China for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's Disease as monotherapy (i.e. without levodopa) or in combination with levodopa - NEUPRO approval in China reinforces UCB's ongoing commitment to supporting patient value across China and to offering Chinese patients additional ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - QBOX IVF streamlines data transfer between lab instruments and Electronic Medical Record providers - Geri® Assess 2.0 enables automatic detection of key events in embryo and blastocyst development, improving efficiencies in assessment - Merck demonstrates commitment to further advance and ...
Astellas Pharma Europe Limited
Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...
Orlando, Florida (ots/PRNewswire) - Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE) study comparing the ...
Orlando, Florida (ots/PRNewswire) - Poster Presentation #1083-P Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults ...
Orlando, Florida (ots/PRNewswire) - Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated the efficacy and safety of ...
Bagsværd, Denmark (ots/PRNewswire) - Oral Presentation #127-OR Adults with type 2 diabetes treated with Xultophy® (insulin degludec and liraglutide injection) also experienced no change in body weight, lower rates of hypoglycaemia and a lower insulin dose at 26 weeks Xultophy® (insulin degludec and liraglutide ...
Darmstadt, Germany (ots/PRNewswire) - - 14 abstracts to be presented, further characterizing the complementary profiles of Mavenclad (cladribine tablets)and Rebif (interferon beta-1a) Merck, a leading science and technology company, will present data from its neurology and immunology portfolio at the 4th Congress of ...
Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the appointment of Dr Alain Munoz to its board of directors. "It is my pleasure to welcome Alain to the board of Oxthera," said Dr. Georges Gemayel, Chairman of Oxthera. ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE ONLY The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that ten company-sponsored abstracts will be presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands being held on 13-16 June. Data from the ...
Brussels (ots/PRNewswire) - - Late-breaking oral presentation on bimekizumab shows significant potential for treating ankylosing spondylitis (AS) - Oral presentation on CIMZIA® (certolizumab pegol) pregnancy outcomes shows no increased risk of major congenital malformations compared to the general population nor an ...
Aachen (ots) - To improve the care of patients with acute or chronic pain, a consortium from academia, small and medium-sized enterprises (SMEs), pain societies, patient organizations and pharmaceutical industry launched the research project "IMI-PainCare - Improving the care of patients suffering from acute or ...